|
|
 |
|
Viewing report
|
|
|
|
Stem Cell Therapy for Cardiac Diseases
BioPolaris, Dec 2009, Pages: 69
Stem Cell Therapy for Cardiac Diseases report features 38 R & D product profiles, 33 company profiles and investors information. This report emphasizes advantages and disadvantages of particular cell therapies for heart diseases, mostly for myocardial infarction and heart failure, characteristics and origin of used cells, mechanism of their action, efficacy and adverse effects, and design of clinical trials.
It appears that the last eight years of prohibition of financing of embryonic stem cells research by the US government, and consequently their use for stem cell-based therapies, had significant negative impact on research and development in this field in the USA. Presently, embryonic stem cells are represented with only 8% among all R & D stem cell-based products undergoing development for the treatment of cardiac diseases. Out of four companies that are conducting development of embryonic stem cell-based therapies for cardiac diseases only two are from the USA. Mesenchymal stem cells (MSCs) obtained from bone marrow hold the dominant place between stem cell therapies undergoing development for cardiac diseases with 45%, followed by peripheral muscle stem cells (13%) and myocardial stem cells (10%). Human embryonic stem cells (hESCs) are used only in 8% of all products (Table 3). Out of 17 R & D products using mesenchymal stem cells 47% are products with undifferentiated MSCs.
The report analysis reveals that unexpectedly high percentage (58%) of all stem cell-based R & D products for the treatment of cardiac diseases is in clinical stage of development, with half of them in advanced clinical stage. In the next 16 months, between December 2009 and April 2012, eight R & D products will complete Phase II and Phase III clinical trials and the value of stem cell-based therapy for cardiac diseases will be much more clear than today.
The anaylst expects that the use of autologous mesenchymal stem cell-derived and human embryonic stem cell derived cardiomyocytes and endothelial cells represent future trend in development of stem cell-based therapy for cardiac diseases.
Customers who bought this item also bought
Stem Cell Therapy for Peripheral Arterial Disease
Stem Cell Therapy for Stroke
Cell and Stem Cell Therapies for Diabetes
Stem Cell Therapy for Spinal Cord Injury
Stem Cell Therapy Perspectives in Treating Motor Neuron Diseases: ALS and SMA
Cardiovascular Drug Delivery - Technologies, Markets and Companies
Global Stem Cell and Advanced Technologies Market
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Drug Delivery in Cancer - Technologies, Markets and Companies
Stem Cell Therapies: Advanced-Stage Clinical Trials
|
|
|
|
